AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib

AbbVie is suffering from Humira biosimilar competition in Europe, but new launches in psoriasis and rheumatoid arthritis could help the drugmaker backfill losses from its top drug. Skyrizi's latest sales figures show how.